In a smaller study of advanced pancreatic cancer patients treated with a combination of agonistic anti-CD40 monoclonal antibodies and chemotherapy (gemcitabine), Wattenberg et al. reported significantly worse OS in patients with high NLR (p = 0.043), suggesting a possible resistance to treatment in states of systemic inflammation [26]. This evidence concerns the gene CD40 and familial pancreatic carcinoma.